Citigroup lowered shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a buy rating to a neutral rating in a report issued on Wednesday morning, MarketBeat.com reports. Citigroup currently has $20.00 price target on the stock, up from their prior price target of $16.00.
Several other brokerages also recently issued reports on HIMS. SVB Leerink started coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They issued a market perform rating and a $10.00 price target on the stock. Imperial Capital upgraded Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 target price on the stock in a report on Wednesday, February 28th. Leerink Partnrs reissued a market perform rating on shares of Hims & Hers Health in a report on Monday, February 26th. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the company a hold rating in a research note on Tuesday, May 7th. Finally, Truist Financial boosted their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a research note on Tuesday, February 27th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of Moderate Buy and a consensus price target of $15.69.
Read Our Latest Report on HIMS
Hims & Hers Health Price Performance
NYSE HIMS opened at $16.18 on Wednesday. The business has a 50 day moving average price of $14.08 and a 200 day moving average price of $11.01. The company has a market capitalization of $3.48 billion, a P/E ratio of -1,618.00 and a beta of 0.97. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $20.11.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter last year, the business posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health will post 0.18 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Hims & Hers Health news, insider Irene Becklund sold 2,747 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $12.08, for a total transaction of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at $66,367.52. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction on Monday, April 1st. The shares were sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Irene Becklund sold 2,747 shares of the stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $12.08, for a total value of $33,183.76. Following the completion of the sale, the insider now owns 5,494 shares of the company’s stock, valued at $66,367.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 594,553 shares of company stock valued at $8,454,738. 17.71% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Hims & Hers Health
Several institutional investors and hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $48,000. Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth $76,000. EMC Capital Management boosted its stake in shares of Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after purchasing an additional 5,332 shares during the period. Certuity LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $109,000. Finally, Corton Capital Inc. purchased a new stake in Hims & Hers Health during the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
See Also
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
